Ryan Schoenfeld, Chief Executive Officer at The Mark Foundation for Cancer Research, shared a post on LinkedIn:
“For over 30 years, progress in treating children’s solid tumors has been agonizingly slow, but that’s finally starting to change.
This week, Mark Johnson at The Washington Post highlighted a groundbreaking clinical trial at Children’s National Hospital led by Dr. Catherine Bollard. This trial, part of the NexTGen team supported by the Cancer Grand Challenges initiative with co-funding from The Mark Foundation for Cancer Research, Cancer Research UK (CRUK), and the NCI, uses an innovative two-pronged CAR T-cell therapy attacking solid tumors in children.
The NexTGen collaboration brings together leading experts from the United States, the UK, and France, combining oncology, immunology, glycobiology, and engineering with one bold goal to make advanced immunotherapies frontline treatments for children with solid tumors within the next decade.
We are proud to support this effort to transform outcomes for young cancer patients worldwide. This reminds us of what’s possible when collaboration crosses disciplines and borders, accelerating breakthroughs in cancer research.”
More posts featuring Ryan Schoenfeld.